Literature DB >> 22343273

Cervical neurofibromatosis with tetraplegia: management by cervical suspensory traction.

Fengliang Wu1, Li Zhang, Zhongjun Liu, Yu Sun, Feng Li, Shenglin Wang, Feng Wei.   

Abstract

STUDY
DESIGN: A case report.
OBJECTIVE: To describe a new method called "cervical suspensory traction" and to report its effect in the treatment of severe cervical kyphotic deformity with neurofibromatosis-1 (NF-1) in a teenager. SUMMARY OF BACKGROUND DATA: Cervical kyphotic deformity exceeding 100° due to NF-1 is a challenging surgical problem. Surgery alone may result in poor corrective efficiency, too long range of fusion, sacrificing more mobile segments.
METHODS: An 18-year-old teenager with NF-1 presented with tetraplegia. Radiographs of the cervical spine revealed that kyphotic deformity of C3-C6 was 125°. Spinal release surgery was undertaken in advance, followed by cervical suspensory traction and subsequent posterior instrumentation and fusion surgery.
RESULTS: During a 4-year follow-up, the patient made a full neurological recovery. Cervical curve of C3-C6 was improved with a residual kyphosis of 30°. Stable bone fusion was obtained in the lower cervical spine. No complication had occurred.
CONCLUSION: Cervical suspensory traction is a viable and safe adjunct technique for applying gradual and sustained effort to maximize postoperative correction in the treatment of NF-1 patients with severely rigid and large curves. This report should contribute to expanding the alternative method for the staged treatment strategy to complex abnormalities.

Entities:  

Mesh:

Year:  2012        PMID: 22343273     DOI: 10.1097/BRS.0b013e31824edd1c

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  1 in total

1.  Clinical outcomes of anterior correction and reconstruction for neurofibromatosis-associated severe cervical kyphotic deformity.

Authors:  Gu Yifei; Shen Xiaolong; Liu Yang; Cao Peng; Yuan Wen
Journal:  Int Orthop       Date:  2018-07-09       Impact factor: 3.075

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.